Berman Brian, Cohen David E, Amini Sadegh
The Center for Clinical and Cosmetic Research, Aventura, Florida USA.
Cutis. 2012 Jun;89(6):294-301.
Actinic keratosis (AK) constitutes the initial epidermal lesion in a disease continuum that may potentially progress to invasive squamous cell carcinoma (SCC). A number of treatment options are available to clear lesions and thus reduce the risk for progression to SCC. Field-directed therapies are primarily used to clear multiple AKs and subclinical lesions. Part 1 of this review explaining the role of field-directed therapy for the treatment of AK discussed the unmet needs with current therapies and the investigational agents that are being developed to fill treatment gaps. Part 2 will mainly focus on field-directed therapies that currently are available for AK, such as resurfacing procedures, patient-administered topical therapy, and photodynamic therapy (PDT), as well as lesion-directed therapy, which is used to clear discrete lesions in relatively small numbers.
光化性角化病（AK）是疾病连续谱中的初始表皮病变，有可能进展为浸润性鳞状细胞癌（SCC）。有多种治疗方法可用于清除病变，从而降低进展为SCC的风险。区域定向疗法主要用于清除多个AK和亚临床病变。本综述的第1部分解释了区域定向疗法在AK治疗中的作用，讨论了当前疗法未满足的需求以及正在开发的用于填补治疗空白的研究药物。第2部分将主要关注目前可用于AK的区域定向疗法，如表面重修手术、患者自行使用的局部治疗和光动力疗法（PDT），以及用于清除数量相对较少的离散病变的病变定向疗法。
